BioSpace.com News

Allied's Herpes Vaccine Progresses to Phase 1 Clinical Trial

Wed, 19 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Brisbane, Australia, 19 June 2013 -- Allied Healthcare Group (ASX: AHZ) has announced that its Herpes Simplex Virus (HSV-2) vaccine has received ethical approval to commence a Phase I, dose ranging, clinical...

Vaxart, Inc.???s Groundbreaking Tablet Influenza Vaccine Generates Protective Antibody Levels in Humans

Wed, 19 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN FRANCISCO--(BUSINESS WIRE)--Vaxart, a privately held company developing recombinant vaccines that are administered by tablet rather than injection, today announced positive safety and immunogenicity data...

Senesco Technologies, Inc. Announces Results of Cohort 2 of its SNS01-T Phase 1b/2a Trial

Wed, 19 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (Senesco or the Company) (OTC QB: SNTI) reported results of cohort 2 in its Phase 1b/2a clinical study of SNS01-T.

Help employers...

University of California, Los Angeles (UCLA) Presents Data on MediciNova, Inc.'s MN-166 in Methamphetamine Addiction at the

Wed, 19 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, June 18, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange...

DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus

Tue, 18 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HOUSTON, June 17, 2013 /PRNewswire/ -- DNAtrix Inc., experts in oncolytic virus development, today announced that...

PhaseBio Pharmaceuticals, Inc. Expands Clinical Development of Vasomera, an Investigational Treatment for Cardiopulmonary Diseases

Tue, 18 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MALVERN, Pa.--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company focused on diabetes and cardiovascular diseases, today announced the successful completion of a Phase 1 trial...

Vaxil Reports Promising Results From Its Follow-Up Clinical Trial of ImMucin in Multiple Myeloma a Patients

Tue, 18 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Ness Ziona, 18th June 2013. Vaxil Bio (TASE: VAXL) which is developing therapeutic vaccinesto treat cancer and infectious diseases, reports promising results that were observed in itsfollow-up study VAXIL...

Cell Therapeutics, Inc. Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients With Myelofibrosis

Mon, 17 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced...

Acetylon Pharmaceuticals Presents Encouraging Safety and Clinical Response Data from Ongoing Clinical Trials of ACY-1215 for the Treatment of Multiple Myeloma

Mon, 17 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals Inc., the leader in development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced the presentation of clinical...

NPS Pharmaceuticals, Inc. Release: Findings Presented at Support Therapeutic Potential of Natpara® as Parathyroid Hormone Replacement Therapy in Patients With Hypoparathyroidism

Mon, 17 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide...

Versartis, Inc. Presents Positive Results From Its First Pediatric Clinical Study of Novel Long-Acting Growth Hormone Treatment at

Mon, 17 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN FRANCISCO, CA--(Marketwired - June 16, 2013) -

Highlighted Links

Array BioPharma, Inc. Announces Positive Interim Results From Combination Trial of ARRY-520 With Kyprolis at the 2013 European

Mon, 17 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOULDER, Colo., June 17, 2013/PRNewswire...

AbbVie Presents Preliminary Results From Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting

Mon, 17 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NORTH CHICAGO, Ill., June 17, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced preliminary results from a...

As the First Biopharmaceutical Company Worldwide, Apceth GmbH Receives Approval for a Clinical Trial With Genetically Modified Adult Mesenchymal Stem Cells for the Treatment of Cancer

Thu, 13 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Munich, Germany, June 13, 2013 / B3C newswire / - As the first biopharmaceutical company worldwide, apceth GmbH & Co. KG with its headquarters and manufacturing sites in Munich and Ottobrunn (near Munich) has...

Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2

Thu, 13 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., June 13, 2013 /PRNewswire/ --Epizyme, Inc....

Omeros Corporation Obtains Regulatory Approval to Initiate Phase 1 Clinical Trial for Lead Antibody in MASP-2 Program

Thu, 13 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SEATTLE, June 13, 2013

Verastem, Inc. Receives Orphan Drug Designation in the EU for VS-6063 in Mesothelioma

Thu, 13 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Cambridge, MA - June 13, 2013 - Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan...

NW Bio Has Initiated Its DCVax®-Direct Phase I/II Trial for All Solid Tumor Cancers

Thu, 13 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BETHESDA, Md., June 13, 2013 /PRNewswire/ --Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology...

Nanobiotix Receives Approval From to Start New Clinical Trial With Lead Product NBTXR3

Thu, 13 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PARIS--(Marketwired - June 13, 2013) - NANOBIOTIX (EURONEXT PARIS: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of...

Derma Sciences, Inc. Reports Results From DSC127 Pharmacokinetic Study

Wed, 12 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces that all data from the pharmacokinetic (PK) study...

SanBio, Inc. Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients With Traumatic Brain Injury

Tue, 11 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MOUNTAIN VIEW, Calif., June 10, 2013 /PRNewswire/ -- SanBio Inc., a California

Immunomedics, Inc. Release: Combination of 90Y-Epratuzumab and Veltuzumab is Active in Non-Hodgkin Lymphoma

Tue, 11 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

VANCOUVER, British Columbia, June 11, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU),a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...

Stemline Therapeutics, Inc.' SL-401 Receives Orphan Drug Designation for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Mon, 10 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, June 10, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) today announced that SL-401 has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the...

Seattle Genetics, Inc. Announces Initiation of Phase 1/2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination With Bendamustine for Hodgkin Lymphoma Patients After Initial Relapse

Mon, 10 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the initiation of a phase 1/2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with bendamustine for...

Concert Pharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of CTP-354, a Potential Treatment for Spasticity and Pain

Mon, 10 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced that it has initiated a Phase 1 clinical trial with CTP-354. CTP-354 is a novel GABAA receptor subtype-selective modulator that...

Bio-Path Holdings, Inc. Successfully Completes Fifth Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia

Fri, 07 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc. (OTCQX: BPTH) (Bio-Path), a biotechnology company developing a liposomal delivery technology for nucleic acid antisense cancer drugs, today announced that...

RXi Pharmaceuticals Announces Positive Results in Its First Double Blind Study in Healthy Volunteers With RXI-109

Thu, 06 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

WESTBOROUGH, Mass., June 6, 2013 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQB: RXII), a biotechnology company...

The Angeles Clinic and Research Institute Releases Interim Data From Study Evaluating Investigational Anti-PD-1 Antibody in Patients With Advanced Melanoma

Wed, 05 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LOS ANGELES--(BUSINESS WIRE)--The Angeles Clinic and Research Institute has released preliminary results from an ongoing Phase IB expansion study evaluating the safety and efficacy of lambrolizumab (MK-347...

Merck & Co., Inc. Melanoma Drug Shrinks Tumors in 38 Percent of Patients: Study

Tue, 04 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

A Merck & Co drug designed to unmask tumor cells and mobilize the immune system into fighting cancer helped shrink tumors in 38 percent of patients with advanced melanoma in an early-stage study, U.S. researchers...

Isis Pharmaceuticals, Inc. Reports Encouraging Data on ISIS-STAT3rx in Patients With Cancer

Tue, 04 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CARLSBAD, Calif., June 3, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced...

ImmunGene, Inc. and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein

Tue, 04 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

THOUSAND OAKS, Calif., June 3, 2013 /PRNewswire/ -- ImmunGene, Inc. today announced that preclinical studies of its...

Debiopharm Announces Additional Phase I Clinical Trial Evaluating Debio 1143 Combined With Chemotherapies for Patients With Selected Solid Malignancies

Tue, 04 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LAUSANNE, Switzerland, June 4, 2013 /PRNewswire/ --

?Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs...

Naurex Inc. Announces Initiation of Phase I Trial for Second-Generation Novel Antidepressant Agent NRX-1074

Tue, 04 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

EVANSTON, Ill., June 4, 2013 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry...

Imperial Innovations Release: Initiates Phase I Trial for Treatment of Hearing Loss and Tinnitus

Tue, 04 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

4 June 2013 -- Imperial Innovations Group plc (AIM: IVO, Innovations, or the Group) a leading technology commercialisation and investment company, announces that its portfolio company, Autifony Therapeutics...

Merrimack Pharmaceuticals Inc. Phase 1 Research Supports MM-121 Potential for Investigation as Combination With Chemotherapy in Patients With Advanced Solid Tumors

Tue, 04 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., June 4, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced results from a Phase 1 clinical study that indicate the novel antibody MM-121 can be combined...

Merrimack Pharmaceuticals Inc.' Phase 1 Research Supports MM-121 Potential for Investigation as Combination With Chemotherapy in Patients With Advanced Solid Tumors

Tue, 04 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., June 4, 2013 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced...

Kinex Pharmaceuticals Announces that the US FDA Allows Their IND to Begin KX02 Clinical Trials

Tue, 04 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BUFFALO, N.Y., June 4, 2013 /PRNewswire/ -- Kinex Pharmaceuticals, Inc. announced today, that the FDA has...

PhaseBio Pharmaceuticals, Inc. Initiated Phase 1 Study of Investigational Once-Weekly Basal Insulin for Potential Treatment of Diabetes

Tue, 04 Jun 2013 12:00:00 AM GMT

Zalicus Inc. Advancing Clinical Development of Z944, Its Novel, Oral, T-Type Calcium Channel Blocker, for the Treatment of Pain

Tue, 04 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (Nasdaq Capital Market: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it...

Tesaro, Inc. Details Niraparib Phase 1 Clinical Data Presented at the 2013 American Society of Clinical Oncology Annual Meeting

Tue, 04 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CHICAGO, June 4, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that final results from a Phase 1 trial of niraparib, an inhibitor of poly...

VBL Therapeutics Release: Phase I/II Data of VB-111 Demonstrate Anti-Tumor Effects With Increase in Overall Survival With This Anti-Angiogenic Gene Therapy, in Patients With Recurrent Glioblastoma Multiforme

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced clinical...

Bristol-Myers Squibb Company Announces Phase 1 Results From First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy® (ipilimumab), in Patients With Advanced Melanoma

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results from Study 004, a dose-ranging Phase 1 trial (n86) evaluating the safety and anti-tumor activity of its investigational...

Ariad Pharmaceuticals, Inc. Presents Updated Phase 1 Data on AP26113 in Patients With Non-Small Cell Lung Cancer

Mon, 03 Jun 2013 12:00:00 AM GMT

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. The study confirms compelling clinical evidence of the anti-tumor activity of AP26113 at multiple dose levels in...

Exelixis, Inc. Presents COMETRIQ™ (cabozantinib) Clinical Trial Data in Patients With Progressive, Metastatic Medullary Thyroid Cancer

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced the presentation of additional data from clinical trials of COMETRIQ (cabozantinib) in patients with progressive, metastatic...

FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients With Head and Neck Cancer

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PRINCETON, N.J., June 3, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical...

Halozyme Therapeutics, Inc.'s Phase 1b Clinical Trial of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, June 3, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced results from a...

Progenics Pharmaceuticals, Inc.' Data From a Phase 1 Study of PSMA ADC Presented at American Society of Clinical Oncology 2013

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TARRYTOWN, N.Y., June 1, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today reported findings from the phase 1 clinical trial in prostate cancer patients of its PSMA ADC compound at...

StemCells Inc.'s Spinal Cord Injury Trial Approved by Health Canada

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEWARK, Calif., June 3, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that Health Canada has authorized the Company to expand its Phase I/II clinical trial for chronic spinal cord injury...

TG Therapeutics, Inc. Announces Presentation of Interim Results From Its Phase I/II Clinical Trial of Single-Agent Ublituximab (TG-1101) in Patients With Rituximab Relapsed/Refractory Non-Hodgkin's Lymphoma

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, June 3, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) today announced preliminary results from a Phase 1 clinical study of single-agent ublituximab (TG-1101) in patients with rituximab relapsed...

Nanobiotix' NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Paris, France, June 3, 2013 NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive Phase I interim results of its...

VBL Therapeutics Release: Phase I/II Data of VB-111 Demonstrate Anti-Tumor Effects With Increase in Overall Survival with This Anti-Angiogenic Gene Therapy, in Patients With Recurrent Glioblastoma Multiforme

Mon, 03 Jun 2013 12:00:00 AM GMT

Curis, Inc. Announces CUDC-427 (GDC-0917) Phase I Clinical Data Presented at American Society of Clinical Oncology 2013 Annual Meeting

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass., June 3, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that...

ZIOPHARM Oncology, Inc. Announces Presentation of Updated Results From Ad-RTS-IL-12 Phase I Study in Advanced Melanoma at the 2013 American Society of Clinical Oncology Annual Meeting

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOSTON, June 1, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced updated results from the Phase 1 study in advanced melanoma using Ad-RTS-IL-12, a novel DNA-based therapeutic candidate...

BioMarin Pharmaceutical Inc. Provides Preliminary Data on Ongoing Phase 1/2 Trial for BMN 673 for the Treatment of Solid Tumors at 2013 American Society of Clinical Oncology Annual Meeting

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN RAFAEL, Calif., June 3, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced an update on the ongoing Phase 1/2 study for its poly ADP-ribose polymerase (PARP) inhibitor BMN...

TopoTarget A/S Release: Positive Data From the BELIEF trial presented at the 2013 American Society of Clinical Oncology Annual Meeting

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Topotarget today announced positive results from the BELIEF trial, a pivotal, single-arm study of belinostat in patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) after failure of ...

EpiCept Corporation Announces New Crolibulin Data Presented at American Society of Clinical Oncology 2013 Support Further Evaluation in Anaplastic Thyroid Cancer

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced thatnew data supporting further evaluation of crolibulin were presented at theAnnual Meeting of the American Society of Clinical...

Karyopharm Therapeutics Presents Clinical Data for Selinexor (KPT-330), a First-in-Class Selective Inhibitor of Nuclear Export (SINE), in Solid Tumors at the 2013 American Society of Clinical Oncology Annual Meeting

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NATICK, Mass., June 2, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, today announced the presentation of clinical data from an ongoing phase...

CytRx Corporation Announces the Presentation of Favorable Results From Novel Combination of Aldoxorubicin and Doxorubicin in a Phase 1b Clinical Trial at American Society of Clinical Oncology Conference

Mon, 03 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that preliminary results from a Phase 1b clinical trial determined that aldoxorubicin...

Omeros Corporation Reports Positive Results From OMS824 Positron Emission Tomography Clinical Trial

Fri, 31 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SEATTLE, May 31, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive results from its Phase...

Virttu Biologics U.S. Phase I Pediatric Study is Extended to Include Systemic Delivery of Oncolytic Virus

Fri, 31 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Glasgow, May 31st 2013: Virttu Biologics Limited (Virttu or the Company), a UK biotechnology company with expertise in the field of oncolytic viruses, is pleased to announce at ASCO that an on-going clinical...

Immunomedics, Inc. Presents Clinical Progress of Antibody-Drug Conjugate Programs at Conference of New York Biotechnology Association

Thu, 30 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MORRIS PLAINS, N.J., May 30, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted...

AtheroNova Inc. Announces Shipment of Phase 1 Drug Product

Thu, 30 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

IRVINE, Calif., May 30, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research...

Helix Biopharma Initiates Enrollment for Fourth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47

Thu, 30 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

AURORA, ON--(Marketwired - May 29, 2013) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical...

Ferring Pharmaceuticals Presents Phase III Data for a Controlled Release Misoprostol Vaginal Delivery System for Labour Induction at the

Tue, 28 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

AMSTERDAM--(BUSINESS WIRE)--Data from the EXPEDITE study presented today at the First European Congress on Intrapartum Care (ECIC) demonstrated that use of a controlled release misoprostol vaginal insert significantly...

Arrowhead Research Corporation Files to Begin Phase 1 Trial of RNAi Therapeutic ARC-520 Against Chronic Hepatitis B Infection

Tue, 28 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it recently filed an application for approval to begin a phase 1 clinical...

Omeros Corporation Files Clinical Trial Application for Lead Antibody in MASP-2 Program

Tue, 28 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SEATTLE, Wash., May 28, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed a...

University of California, Irvine Researchers Demonstrate Drug Candidate ShK-186, Derived From Sea Anemone Venom, Effective in Anti-Obesity Studies

Tue, 28 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

IRVINE, Calif. & SEATTLE--(BUSINESS WIRE)--Scientists at UC Irvine reported this week that a synthetic compound ShK-186, originally derived from a sea anemone toxin, has been found to enhance metabolic activity...

Promedior Presents Encouraging Results From Clinical Study of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis

Thu, 23 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass.--(BUSINESS WIRE)-- Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, unveiled data from a clinical study of PRM-...

Virobay Inc. Initiates a Phase 1 Trial of VBY-036, a Compound Intended for the Treatment of Neuropathic Pain

Thu, 23 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MENLO PARK, Calif., May 23, 2013 /PRNewswire/ -- Virobay, Inc. today announced that their development of an oral treatment...

Spring Bank Pharmaceuticals, Inc. Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients

Thu, 23 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MILFORD, Mass., May 23, 2013 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing...

First Patient Dosed in the Phase I/II Study of Candidate Drug for Premenstrual Dysphoric Disorder

Thu, 23 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

STOCKHOLM May 23, 2013. Umecrine Mood AB announced today that dosing has beeninitiated in a randomized Phase I/II study of UC1010 for the treatment ofpatients with premenstrual dysphoric disorder (PMDD...

Protalex, Inc. Reports Positive Interim Review of Phase 1b Trial of PRTX-100 in Rheumatoid Arthritis by Independent Data Safety Monitoring Committee

Wed, 22 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SUMMIT, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim safety review by its independent Data Safety Monitoring...

Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer

Wed, 22 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PALO ALTO, Calif., May 22, 2013 /PRNewswire/ -- Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has...

ChemoCentryx, Inc. Announces Phase I Data With CCX507, Company's New Generation Orally Administered CCR9 Inhibitor

Tue, 21 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MOUNTAIN VIEW, Calif. and ORLANDO, Fla., May 21, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced data showing that CCX507, a next generation orally available inhibitor of the chemokine receptor...

Medivir AB Release: Positive Results From a Phase Ia Study With MIV-711 for the Treatment of Skeletal Disorders

Tue, 21 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Stockholm, Sweden Medivir AB (OMX:MVIR) announced that data from a first inman study on the investigational cathepsin K inhibitor MIV-711 for the treatmentof osteoarthritis and osteoporosis was presented...

NeuroSigma, Inc. Release: Positive Results Reported for Phase I Clinical Trial at University of California, Los Angeles (UCLA) for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)

Tue, 21 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LOS ANGELES, May 20, 2013 /PRNewswire/ -- Today, at the American Psychiatric Association (APA) Meeting in

CytRx Corporation Announces Initial Results From Pharmacokinetics Clinical Trial With Aldoxorubicin in Solid Tumors

Tue, 21 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced initial data from a Phase 1b clinical trial evaluating...

Addex Therapeutics Validates Potential Efficacy Biomarker for Phase 1 Trial of Its GABA-B Positive Allosteric Modulator, ADX71441

Tue, 21 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PLAN-LES-OUATES GENEVA, SWITZERLAND--(Marketwired - May 21, 2013) -

Addex Therapeutics / Addex Validates Potential Efficacy Biomarker for Phase1 Trial of itsGABA-B...

Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis

Mon, 20 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PALO ALTO, Calif., May 17, 2013 /PRNewswire/ -- Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has...

Immunicum AB Release: Promising Data for Cancer Vaccine INTUVAX™ in the Treatment of Kidney Cancer

Mon, 20 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Immunicum AB (publ) presents a status update with promising data from an ongoing clinical phase I/II-study of the cancer vaccine INTUVAX in the treatment of metastatic renal cell carcinoma. Two patients with...